Evotec SE
General ticker "EVOTF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.4B (TTM average)
Evotec SE does not follow the US Stock Market performance with the rate: -16.0%.
Estimated limits based on current volatility of 1.3%: low 6.58$, high 6.72$
Factors to consider:
- Total employees count: 203 as of 2007
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.76$, 9.45$]
- 2026-12-31 to 2027-12-31 estimated range: [4.42$, 8.81$]
Short-term EVOTF quotes
Long-term EVOTF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €781.43MM | €796.97MM | €788.08MM |
| Operating Expenses | €828.93MM | €939.49MM | €928.90MM |
| Operating Income | €-47.51MM | €-142.52MM | €-140.82MM |
| Non-Operating Income | €-33.09MM | €-51.45MM | €12.49MM |
| Interest Expense | €11.74MM | €11.70MM | €14.44MM |
| R&D Expense | €73.90MM | €50.86MM | €77.35MM |
| Income(Loss) | €-80.59MM | €-193.98MM | €-128.33MM |
| Taxes | €3.32MM | €2.10MM | €-24.85MM |
| Profit(Loss)* | €-83.91MM | €-196.08MM | €-103.48MM |
| Stockholders Equity | €1,119.91MM | €952.52MM | €813.40MM |
| Inventory | €30.89MM | €31.12MM | €29.31MM |
| Assets | €2,252.47MM | €1,912.50MM | €1,778.09MM |
| Operating Cash Flow | €36.44MM | €18.22MM | €-9.43MM |
| Capital expenditure | €216.00MM | €132.24MM | €72.51MM |
| Investing Cash Flow | €-13.29MM | €-71.19MM | €166.36MM |
| Financing Cash Flow | €71.96MM | €-161.42MM | €-32.19MM |
| Earnings Per Share** | €-0.47 | €-1.11 | €-0.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.